Gilead’s Once-Weekly Yeztugo Accepted by FDA for HIV Prevention Review
FOSTER CITY, Calif., June 16, 2026 Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has...
Licensing Agreements
Advertisement
Halia Therapeutics Secures FDA Fast Track for Ofirnoflast
LEHI, Utah, June 15, 2026 Halia Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted...
Halozyme Reaffirms Long-Term Royalty Growth Despite Proposed Medicare Pricing Changes
SAN DIEGO, June 15, 2026 Halozyme Therapeutics, Inc. has confirmed that it expects zero to minimal impact on royalty...
Advertisement
